 CHERRY HILL, N.J., Aug. 15, 2022 GLOBE NEWSWIRE -- Vyant Bio, Inc. Vyant Bio or Company Nasdaq: VYNT is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Companys proprietary central nervous system CNS drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it is postponing its investor conference call for the second quarter and first half of 2022, originally scheduled for Monday, August 15, 2022 at 4:30 pm ET. 